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Abstract
Background: Dominant mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of
Parkinson’s disease, however, the underlying pathogenic mechanisms are poorly understood. Several in vitro studies have
shown that the most frequent mutation, LRRK2(G2019S), increases kinase activity and impairs neuronal survival. LRRK2 has
been linked to the mitogen-activated protein kinase kinase kinase family and the receptor-interacting protein kinases based
on sequence similarity within the kinase domain and in vitro substrate phosphorylation.
Methodology/Principal Findings: We used an unbiased proteomic approach to identify the kinase signaling pathways
wherein LRRK2 may be active. By incubation of protein microarrays containing 260 signal transduction proteins we detected
four arrayed Ste20 serine/threonine kinase family members (TAOK3, STK3, STK24, STK25) as novel LRRK2 substrates and
LRRK2 interacting proteins, respectively. Moreover, we found that protein kinase C (PKC) zeta binds and phosphorylates
LRRK2 both in vitro and in vivo.
Conclusions/Significance: Ste20 kinases and PKC zeta contribute to neuronal Tau phosphorylation, neurite outgrowth and
synaptic plasticity under physiological conditions. Our data suggest that these kinases may also be involved in synaptic
dysfunction and neurite fragmentation in transgenic mice and in human PD patients carrying toxic gain-of-function LRRK2
mutations.
Citation: Zach S, Felk S, Gillardon F (2010) Signal Transduction Protein Array Analysis Links LRRK2 to Ste20 Kinases and PKC Zeta That Modulate Neuronal
Plasticity. PLoS ONE 5(10): e13191. doi:10.1371/journal.pone.0013191
Editor: Alfred Nordheim, University of Tuebingen, Germany
Received June 2, 2010; Accepted September 7, 2010; Published October 7, 2010
Copyright:  2010 Zach et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors are employees of Boehringer Ingelheim Pharma GmbH & Co KG. The funder has approved submission of the manuscript. The funder did
play a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript.
Competing Interests: The authors are employees of Boehringer Ingelheim Pharma GmbH & Co KG. Funding does not alter adherence to all the PLoS ONE
policies on sharing data and materials.
* E-mail: Frank.Gillardon@boehringer-ingelheim.com
Introduction
Parkinson’s disease (PD) is the second most prevalent neurode-
generative disorder and is pathologically characterized by the
selective loss of dopaminergic neurons in the substantia nigra
causing motor dysfunction. Although the etiology of PD is
incompletely understood, genetic studies have identified mutations
in several genes that segregate with rare familial forms of the
disease [1]. Mutations in the PARK8 gene encoding leucine-rich
repeat kinase 2 (LRRK2) are the most prevalent cause of
autosomal dominantly inherited PD and are characterised by
typical brainstem Lewy body pathology [2]. The most frequent
mutation, LRRK2(G2019S), is found in the kinase domain and is
responsible for approximately 1% of sporadic PD and 5% of
familial cases in Caucasians. LRRK2 is a 286 kDa protein
containing an N-terminal leucine-rich repeat, a Ras of complex
protein (Roc) GTPase domain, a C-terminal of Roc (Cor) region, a
kinase domain, and a WD40 protein interaction domain. Several
studies have shown that the G2019S mutation enhances kinase
activity in vitro and that kinase activity mediates degeneration in
transfected neurons. Although the kinase domain of LRRK2
exhibits some sequence homology to the mitogen-activated protein
(MAP) kinase kinase kinase family, LRRK2 does not seem to act
within classical MAP kinase signaling cascades and its upstream
regulators / downstream effectors remain to be identified [3,4]. By
protein-protein interaction analysis binding of LRRK2 to the
Hsp90/Cdc37 chaperone complex, C-terminus of Hsp70-inter-
acting protein, and parkin has been detected which may influence
the folding and degradation of LRRK2 [5,6]. Potential LRRK2
protein substrates include moesin, eukaryotic initiation factor 4E-
binding protein (4E-BP), and tubulin-beta, however their physi-
ological relevance remains unclear [7]. In the present study, we
used protein microarrays containing about 260 human signal
transduction proteins in order to identify the signaling networks
wherein LRRK2 may be active.
Methods
Expression and purification of recombinant proteins
Full-length human LRRK2 expression constructs were gener-
ated as described in detail elsewhere [8]. The PD-linked
LRRK2(G2019S) mutation was introduced by site-directed
mutagenesis. LRRK2 constructs were tagged with a StrepII/Flag
tag at their C-terminus and cloned into a pFastBac vector for
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DNA was generated by transformation of competent DH10Bac E.
coli cells using the Bac-to-Bac expression system according to the
manufacturer’s protocol (Invitrogen, Carlsbad, USA). Recombi-
nant baculovirus was isolated from Sf9 cell culture supernatant five
days after transfection with LRRK2 Bacmid DNA. Viral titer was
determined using the BaculoTiter assay kit (Invitrogen, Carlsbad,
USA).
Suspension cultures of High Five insect cells were infected with
baculovirus at a multiplicity of infection of 10. Two days later cells
were lysed in a buffer containing 100 mM Tris, pH 7.4, 130 mM
NaCl, 1 mM sodium fluoride, 1% Triton X-100 and protease
inhibitor cocktail (Sigma, Taufkirchen, Germany). Recombinant
LRRK2 was purified from the supernatant by StrepTactin
Superflow affinity chromatography according to the manufactur-
er’s instructions (IBA GmbH, Go ¨ttingen, Germany). Purified
protein was stored at 280uC in elution buffer (100 mM Tris,
pH 8.0, 150 mM NaCl, 1 mM EDTA) containing 10% glycerol,
0.1 mM EGTA, 0.3% Brij-35.
N-terminal GST-tagged human LRRK2 fragments (amino
acids 970-2527) were purchased from Invitrogen (Invitrogen,
Carlsbad, USA). N-terminal His-tagged MARKK(K57A) was
acquired from the Max-Planck-Institute for Structural Molecular
Biology (Hamburg, Germany). The kinase-dead MARKK mutant
was generated as described elsewhere [9]. Storage buffer was
exchanged to kinase assay buffer using Vivaspin 500 columns
(Sartorius, Goettingen, Germany). N-terminal His-tagged human
PKC zeta was provided by the University of Dundee (UK).
Kinase substrate identification using protein arrays
Panorama Human Protein Function Array – Signal Transduc-
tion (Sigma, Saint Louis, USA) were used according to the
manufacturer’s protocol with modifications. These arrays contain
a set of 259 full-length human signaling proteins tagged with a
biotin-carboxyl carrier protein. The tag is biotinylated only when
the fusion protein is correctly folded during expression in insect
cells and enables oriented immobilization on streptavidin-coated
glass slides. Arrays were washed twice for 5 min in 5 ml assay
buffer (250 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.1 mM
EGTA, 2 mM DTT, 1 mM NaO3V, 0.1% BSA, 20% glycerol
and 0.1% Triton X-100)., To prevent interference with the
detection of LRRK2-specific signals, autophosphorylation of
active kinases spotted on the arrays was completed by pre-
incubation in assay buffer containing 100 mM cold ATP only. It
should be noted that this pre-incubation step will also preclude
detection of a potential LRRK2-mediated phosphorylation of
kinase autophosphorylation sites. GST-tagged LRRK2(G2019S)
(970-2527) or inactive LRRK2-(D1994A) (970-2527) (Invitrogen,
Carlsbad, USA) were diluted in assay buffer containing cold ATP
(final concentration 10 mM) and [c-
33P]ATP (30 mCi final activity)
in a total volume of 120 ml. Kinases (130 nM) or buffer only
(negative control) were overlaid on the arrays, covered with
HybriSlip
TM cover slips (Aldrich, St. Louis, USA), placed in
quadriPerm culture vessels, and incubated for 1 hour at 30uC.
Subsequently, arrays were washed in 0.5% sodium dodecyl sulfate
(SDS) in assay buffer, followed by assay buffer and ultra-pure
water. After centrifugation at 8006g for 4 minutes, arrays were
exposed to phosphoscreens (GE Healthcare, Munich, Germany)
or X-ray films (Kodak, Stuttgart, Germany). The phosphoscreens
were scanned on a Typhoon 9400 laser scanner (GE Healthcare,
Munich, Germany) at a resolution of 25 mm and analyzed using
Genepix Pro 6.0 software (Molecular Devices Corporation,
Sunnyvale, USA) followed by ProtoArray Prospector Analyzer
3.0 software (Invitrogen, Carlsbad, USA). Potential kinase
substrates are defined as spotted proteins exhibiting a normalized
phosphorylation signal greater 150% of the phosphorylation signal
observed on the negative control array and greater 2 standard
deviations than the median signal/background value for all negative
control spots on the array. Further information about protein
array content and data analysis are available from http://www.
sigmaaldrich.com/etc/medialib/docs/Sigma/General_Information/
hpfm4techbulletin.Par.0001.File.tmp/hpfm4techbulletin.pdf.
Protein-protein binding studies using protein arrays
For protein-protein binding studies, GST-tagged LRRK2(G2019S)
(970-2527) was autophosphorylated in assay buffer containing 10 mM
cold ATP for 1 h at 30uC. Arrays were washed and equilibrated in
assay buffer as described above. Thereafter, arrays were overlaid with
autophosphorylated LRRK2 for 1 h at 30uC. Incubation with
recombinant GST (GenWay, San Diego, USA) expressed in E. coli
was tested as control. After washing in 0.5% SDS containing buffer,
arrays were blocked 5 min in blocking buffer (phosphate-buffered
saline, 0.1% Tween, 20% glycerol, 2% BSA and 1 mM dithiothreitol)
twice. Arrays were then incubated with an anti-GST Alexa 488-
conjugated antibody (Millipore, Schwalbach, Germany) (1:250) over
night at 4uC. After two washing steps in blocking buffer and one in
PBS, arrays were scanned using a Typhoon 9400 laser at 488 nm
excitation and 520 nm emission at a resolution of 100 mm. Cy3-
labeled reference protein spots which alleviate grid orientation in
analysis were scanned at 532 nm excitation and 580 nm emission.
Spotted proteins are considered as potential interactors, if the
normalized fluorescence signal is greater 150% of the fluorescence
signal observed in the negative control assay and greater 2 standard
deviations than the median signal/background value for all negative
control spots on the array.
Kinase assay in solution
Kinase assay were performed in 15 ml assay buffer (25 mM
Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM dithio-
threitol, 1 mM Na3VO4) containing 0.25 mg GST-tagged
LRRK2, 30 mCi [c-
33P]ATP and 100 mM ATP at 30uC for
45 min. Both recombinant His-tagged PKC zeta and His-tagged
MARKK(K57A) were tested as substrates (1 mg each). Full-length
LRRK2, recombinant GST (GenWay, San Diego, USA), and
GST-tagged moesin (University of Dundee, Dundee, UK) were
assayed as well. The kinase reaction was stopped with 46Laemmli
buffer, and the samples were heated for 10 minutes to 75uC.
Subsequently, proteins were separated on 4–12% sodium dodecyl
sulphate, Bis-Tris polyacrylamide minigels (Invitrogen, Karlsruhe,
Germany). The gels were dried for 1 h at 80uC in a vacuum gel
dryer (Model 583, Biorad, Hercules, USA), and were exposed to
phosphoscreens for 24 h at 280uC. Phosphoscreens were imaged
on a Typhoon 9400 laser scanner (GE Healthcare, Freiburg,
Germany) and quantified using Quantity One software (Biorad,
Munich, Germany).
Immunoprecipitation
Animal work was approved by the Regierungspraesidium
Tuebingen (ID 10-004). C75BL/6 mice were killed by cervical
dislocation followed by decapitation. The brains were rapidly
removed and placed into ice-cold PBS. The brains were
homogenized in 1:5 (w/v) ice-cold lysis buffer (50 mM Tris
pH 7.5, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM
Na3VO4, 5 mM sodium pyrophosphate, 50 mM sodium fluorid,
1% Triton X-100, 0.1% 2-mercaptoethanol, 1 mM benzamidine,
1 mM PMSF) in a Teflon-glass douncer. Lysates were centrifuged
at 160006g for 15 min at 4uC. Aliquots of the supernatants were
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(Biorad, Munich, Germany).
Three mg total protein were used per reaction. Lysate volume
was made up to 700 ml with lysate buffer. PKC zeta was
immunoprecipitated using an affinity-purified goat polyclonal
antibody (Santa Cruz Biotechnology, Heidelberg, Germany). Pre-
immune serum was used as negative control. Protein G-agarose
beads (Protein G Immunoprecipitation Kit, Sigma, Saint-Louis,
USA) were incubated with antibody or pre-immunue serum for
4 h at 4uC under constant agitation. The beads were pelleted by
centrifugation at 40006g for 3 min at 4uC. The supernatants were
removed, and the beads were resuspended in 1 ml of lysis buffer.
The wash step was repeated once. Thereafter, brain lysates were
added and incubated over night at 4uC under constant agitation.
Beads were pelleted and washed sequentially with lysis buffer plus
0.5 M NaCl, lysis buffer alone, and PBS. After a final
centrifugation step beads were resuspended in 20 ml Laemmli
buffer (1% sodium dodecyl sulfate, 100 mM dithiothreitol, 50 mM
Tris, pH 7.5) and heated to 50uC for 15 min. The supernantants
were separated from the beads by centrifugation in spin columns
(Protein G Immunoprecipitation Kit, Sigma, Saint-Louis, USA),
heated up to 75uC for 10 min and subjected to gel electrophoresis
followed by immunoblotting.
Gel Electrophoresis and Immunoblotting
Samples were resolved by electrophoresis on 4–12% NuPAGE
Bis-Tris gradient gels according to manufacturer’s instructions
using NuPAGE MOPS running buffer (Invitrogen, Carlsbad,
USA). After transfer to nitrocellulose membranes (Protran,
Schleicher and Schuell, Dassel, Germany) membranes were
blocked for 1 h at 20uC in 5% skimmed milk powder in Tris-
buffered saline and 0.1% Tween. Membranes were then incubated
overnight at 4uC with either an goat polyclonal antibody against
PKC zeta (Santa Cruz Biotechnology, Heidelberg, Germany) or a
rat monoclonal antibody against LRRK2 (clone 1E11, GSF,
Munich, Germany) (1 mg/ml each). Horseradish peroxidase-
conjugated secondary antibodies and enhanced chemilumines-
cence reagents (ECL kit, GE Healthcare, Freiburg, Germany)
were used for detection. Membranes were checked for protein load
and protein transfer using a protein staining kit (MemCode,
Pierce, Rockford, USA) that reversibly stains for total protein.
Densitometric analysis of immunoblots was performed using
Quantity One software (Biorad, Munich, Germany).
Statistical analysis
All experiments were performed at least twice. Statistical
significance was determined by performing a two-tailed Student’s
t-test using GraphPad Prism Version 5.00 (GraphPad software, La
Jolla, USA). A p-value,0.05 was considered significant.
Results
Panorama Human Protein Functional Arrays were incubated in
assay buffer containing [c-
33P]-ATP and either GST-tagged
LRRK2(G2019S) or buffer only. After several washing steps the
arrays were imaged using phosphoscreens and a Typhoon 9400
laser scanner. Genepix Pro digital image analysis followed by
ProtoArray Prospector Analyzer statistical analysis (see Table S1)
revealed a significant increase in radioactive signal intensity on the
LRRK2-treated protein microarrays in the spotted proteins that
are listed in Table 1. Four members of the Ste20 serine/threonine
kinase family (TAOK3, STK3, STK24, STK25) [10] were
identified as potential LRRK2 substrates. LRRK2 has been
classified as receptor-interacting protein kinase 7 (RIP7) and trans-
phosphorylation between RIP kinases has been demonstrated by
others [11]. Consistently, receptor-interacting protein kinase 2
(RIP2), the only RIP kinase family member spotted, is phosphor-
ylated by LRRK2. Magnified sections of the arrays are shown in
Figure 1 and 2. In addition, increased signal intensity of the
quadruplicate spots of PKC zeta on the LRRK2-treated arrays is
shown in Figure 3A.
In order to confirm the data from protein array analysis, we first
tested whether LRRK2 was able to phosphorylate PKC zeta in a
kinase assay in solution, since PKC zeta plays a central role in
neuronal physiology [12]. Surprisingly, incubation of recombinant
full-length PKC zeta with LRRK2(G2019S) did not result in
LRRK2-mediated PKC zeta phosphorylation (data not shown).
These findings led us to assume that the radioactive signal on the
protein arrays resulted from binding of
33P-autophosphorylated
LRRK2(G2019S) to spotted PKC zeta. For protein-protein
Table 1. Proteins spotted on functional human protein arrays showing increased signal intensity following incubation with
recombinant LRRK2(G2019S).
Protein Accession number Signal/Control
Protein phosphorylation
Thousand-and-one amino acids kinase 3 (TAOK3) Q9UHG7 2.2
Receptor-interacting serine-threonine kinase 2 (RIPK2) O43353 2.0
Protein kinase C, zeta (PRKCZ) Q05513 1.5
Serine/threonine kinase 3 (STE20 homolog, yeast (STK3) Q13188 1.5
Serine/threonine kinase 24 (STE20 homolog, yeast (STK24) Q9Y6E0 1.5
Serine/threonine kinase 25 (STE20 homolog, yeast (STK25) O00506 1.5
Protein-protein interaction
Serine/threonine kinase 25 (STE20 homolog, yeast) (STK25) Q00506 2.3
Protein kinase C, zeta (PRKCZ) Q05513 2.1
Heat shock 90kDa protein, alpha (HSPCA) P07900 1.6
Serine/threonine kinase 24 (STE20 homolog, yeast) (STK24) Q9Y6E0 1.6
TNF receptor-associated factor 2, transcript variant 1 (TRAF2) Q12933 1.5
doi:10.1371/journal.pone.0013191.t001
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were incubated with GST-tagged LRRK2(G2019S) or recombi-
nant GST as control in the presence of cold ATP. Binding of
LRRK2(G2019S) to arrayed proteins was analyzed by a
subsequent incubation with an Alexa 488-conjugated anti-GST
antibody. The arrays were imaged directly on a Typhoon 9400
laser scanner and analysed by Genepix Pro followed by
ProtoArray Prospector software (see Table S2). As can be seen
from Figure 3B, a significantly higher green fluorescence signal of
the quadruplicate PKC zeta spots was detected when compared to
the corresponding spots on the control arrays. In addition, STK24
and STK25, which were already identified as potential LRRK2
substrates (shown above), were detected as LRRK2 binding
proteins (Table 1; Figure 1B). Interacting proteins also included
heat shock protein 90, which has already been identified as
LRRK2 binding/stablising protein by others [13], and tumor
necrosis factor receptor-associated factor 2 (TRAF2) (Table 1).
At this stage of our study, kinase-inactive LRRK2(D1994A)
became commercially available. We confirmed that GST-tagged
LRRK2(D1994A) lacks autophosphorylation activity in a solution
kinase assay (data not shown). Thereafter, substrate identification
studies on protein arrays were repeated using active
LRRK2(G2019S) and kinase-dead LRRK2(D1994A) as negative
control. Surprisingly, protein arrays incubated with inactive
LRRK2(D1994A) showed a significant increase in the radioactive
signals on the PKC zeta spots compared to buffer controls, which
is similar to arrays treated with active kinase (Figure 3C). These
findings so far allowed us only to conclude that LRRK2 binds to
spotted PKC zeta and becomes phosphorylated by PKC zeta on
the array during incubation. This conclusion was tested in a kinase
assay in solution. By incubating LRRK2(G2019S), inactive
LRRK2(D1994A), or wildtype LRRK2 with recombinant PKC
zeta and [c-
33P]ATP, we could demonstrate that LRRK2 was
efficiently phosphorylated by PKC zeta in vitro (Figure 4). In order
to exclude that the GST-tag on recombinant LRRK2 is
phophorylated by PKC zeta, kinase assays were performed using
recombinant GST and GST-tagged proteins leading to negative
results (Figure 4). We also confirmed that PKC zeta is able to
phosphorylate full-length LRRK2 (Figure 5). To demonstrate in
vivo interaction between LRRK2 and PKC zeta, we used brain
homogenates of wildtype C75BL/6 mice, since PKC zeta is highly
expressed in the brain. As shown in Figure 6, endogenous LRRK2
can be co-immunoprecipitated with PKC zeta indicating physi-
ological relevance. The functional consequence of PKC zeta-
mediated LRRK2 phosphorylation on LRRK2 enzymatic activity
could not be clarified, since PKC zeta efficiently phosphorylated
heat-treated moesin (Fig. S1), a validated LRRK2 substrate
[14,15].
Figure 2. LRRK2 phosphorylates receptor interacting kinase 2
on protein microarrays. Magnified sections of Panorama Human
Protein Function Arrays incubated with LRRK2(G2019S) and [c-
33P]ATP
(left panel) or buffer and [c-
33P]ATP (right panel). The quadruplicate
spots of receptor interacting kinase 2 exhibit an increased radioactive
signal when incubated with recombinant LRRK2(G2019S).
doi:10.1371/journal.pone.0013191.g002
Figure 3. LRRK2 binds to spotted protein kinase C zeta and
becomes phosphorylated. Panorama Human Protein Function
Arrays incubated with (A) GST-tagged LRRK2(G2019S) and [c-
33P]ATP
(left panel) or buffer and [c-
33P]ATP (right panel), (B) GST-tagged
LRRK2(G2019S) and cold ATP or recombinant GST and cold ATP, (C)
kinase-inactive GST-tagged LRRK2(D1994A) and [c-
33P]ATP or buffer
and [c-
33P]ATP. (A and C) An increase in radioactive signal intensity is
visibly on the LRRK2-treated protein arrays in the quadruplicate spots of
protein kinase C zeta. (B) GST-tagged LRRK2 bound to spotted protein
kinase C zeta is visualized by an Alexa 488-conjugated anti-GST
antibody. Control arrays show background signal only. Orange
fluorescence of Cy3-labeled duplicate protein spots is visible in the
upper left corner which serve as markers for grid alignment during
image analysis.
doi:10.1371/journal.pone.0013191.g003
Figure 1. Recombinant LRRK2 binds and phosphorylates
arrayed serine/threonine kinase 25. (A) Magnified sections of
Panorama Human Protein Function Arrays incubated with GST-tagged
LRRK2(G2019S) (amino acids 970-2527) and [c-
33P]ATP (left panel) or
buffer and [c-
33P]ATP (right panel). The phosphoscreen image shows an
increase in radioactive signal intensity on the LRRK2-treated protein
arrays in the quadruplicate spots of serine/threonine kinase 25. (B)
Arrays incubated with GST-tagged LRRK2(G2019S) and cold ATP (left
panel) or recombinant GST and cold ATP (right panel). GST-tagged
LRRK2 bound to spotted serine/threonine kinase 25 is detected by an
Alexa 488-conjugated anti-GST antibody. The GST-treated control array
is negative. Orange fluorescence of Cy3-labeled duplicate protein spots
is visible in the upper left corner which serve as markers for grid
alignment during image analysis.
doi:10.1371/journal.pone.0013191.g001
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detected as in vitro LRRK2 substrates, TAOK3 is of particular
interest. TAO kinases exhibit high sequence homology to
microtubule affinity-regulating kinase-activating kinase (MARKK)
[16]. MARKK phosphorylates/activates MARK which phos-
phorylates the microtubule-associated protein Tau [9]. A de-
crease/increase in Tau phosphorylation has been demonstrated in
mouse mutants lacking/overexpressing LRRK2, although Tau is
not a direct substrate of LRRK2 [17,18]. A kinase signaling
cascade LRRK2RMARKKRMARK might explain enhanced
Tau phosphorylation in brains from LRRK2 overexpressing mice
and from human PD patients carrying a gain-of-function
LRRK2(G2019S) mutation [2]. To assess phosphorylation of
recombinant MARKK by LRRK2 in solution, kinase-dead
MARKK(K57A) was incubated with LRRK2(G2019S). As shown
in Figure 7, MARKK(K57A) becomes phosphorylated by LRRK2
to a similar extent as tubulin-beta that is co-purified with
recombinant LRRK2 [18].
Discussion
Mutations in LRRK2 represent the most prevalent cause of PD,
however the (patho)physiological functions of LRRK2 remain
poorly understood. Based on sequence similarities in the conserved
kinase domains, LRRK2 has been classified as a member of the
receptor-interacting protein (RIP) family kinases that integrate
both extracellular and intracellular stress signals [19]. Like RIP1,
Figure 4. Recombinant protein kinase C zeta phosphorylates a
LRRK2 fragment in solution. (Upper panel) Autoradiogram demon-
strating phosphorylation of GST-tagged LRRK2(G2019S) (amino acids
970-2527) (lane 1), GST-tagged wildtype LRRK2 (lane 2) and kinase-
inactive GST-tagged LRRK2(D1994A) (lane 3) by recombinant protein
kinase C zeta in vitro. Background autophosphorylation of the three
kinases in the absence of protein kinase C zeta is shown in lanes 5–7.
GST-tagged moesin is not a substrate for protein kinase C zeta
excluding GST phosphorylation by protein kinase C zeta (lane 4). (Lower
panel) Coomassie Blue protein staining of the gel shows similar
amounts of recombinant LRRK2.
doi:10.1371/journal.pone.0013191.g004
Figure 5. Protein kinase C zeta phosphorylates full-length LRRK2
in vitro. (Upper panel) Autoradiogram showing phosphorylation of full-
length, wildtype LRRK2 (lane 2, 4) and full-length, kinase-dead
LRRK2(K1906M) (lane 1, 3) by recombinant protein kinase C zeta (lane 1,
2) in vitro.( L o w e rp a n e l )C o o m a s s i eB l u ep rotein staining shows similar
amounts of recombinant LRRK2. Two LRRK2 fragments are visible migrating
below 250 kDa that are also phosphorylated by protein kinase C zeta.
doi:10.1371/journal.pone.0013191.g005
Figure 6. LRRK2 co-immunoprecipitates with protein kinase C
zeta from mouse brain. Homogenates of C57BL/6 mouse brains
were incubated with an anti-protein kinase C zeta antibody (lane 2) or
pre-immune serum as control (lane 1). Immuncomplexes were
precipitated using protein G-sepharose beads and subjected to gel
electrophoresis and immunoblotting using either an anti-LRRK2
antibody (upper panel) or an anti-protein kinase C zeta antibody
(lower panel). Representative results are shown for experiments that
were repeated two times.
doi:10.1371/journal.pone.0013191.g006
Figure 7. LRRK2 phosphorylates MARKK in vitro. (Left panel)
Autoradiogram showing phosphorylation of recombinant, kinase-
inactive MARKK(K57A) by GST-tagged LRRK2(G2019S) (amino acids
970-2527) (lane 2). Kinase-inactive GST-tagged LRRK2(D1994A) was
used as negative control (lane 1). Endogenous tubulin-beta that is co-
purified with LRRK2 becomes phosphorylated as well. (Right panel)
Coomassie Blue protein staining shows similar amounts of recombinant
proteins.
doi:10.1371/journal.pone.0013191.g007
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adaptor proteins of death receptors (e.g. TNF-alpha, Fas),
indicating that LRRK2 may act within the extrinsic cell death
signaling pathway [20]. Imai and colleagues [21] reported that
LRRK2 phosphorylates eukaryotic initiation factor 4E-binding
protein (4E-BP), a key regulator of protein translation during cell
stress, and that LRRK2 genetically interacts with the Rheb
GTPase / Tor kinase / 4E-BP signaling pathway in Drosophila.
Furthermore, mitogen-activated protein kinase kinases (MKK) 4
and 7 become phosphorylated by LRRK2 in vitro suggesting that
LRRK2 may represent an upstream component of the MAP
kinase signaling cascade [22].
In the present study, we used protein microarrays containing a
set of 259 human recombinant proteins that are involved in key
signaling networks (including TNF receptor signaling, MAP kinase
signaling) in order to identify potential LRRK2 substrates or
interactors and to map LRRK2 to specific signaling pathways. Of
the published LRRK2 substrates, both 4E-BP and MKK7 are
spotted on the arrays, however neither protein became phosphor-
ylated following array incubation with recombinant LRRK2.
Recently, Kumar and colleagues [23] reported that the stochio-
metry of LRRK2-mediated 4E-BP phosphorylation in vitro is low
and that 4E-BP phosphorylation in HEK293 cells does not change
following LRRK2 overexpression suggesting that 4E-BP is not a
major substrate of LRRK2. Similarly, we could not detect an
increase in phospho-MKK7(S271/T275) levels in LRRK2
overexpressing HEK293 cells by immunoblot analysis (data not
shown). Novel potential substrates/interactors of LRRK2 that we
identified by protein array analysis included four members of
Ste20 serine/threonine kinase family (TAOK3, STK3, STK24,
STK25) [24]. Other kinases, like AKT, Raf-1, and PKA have
already been shown to bind/phosphorylate STK3 or STK24,
thereby modulating kinase activity [25]. Both STK24 and STK25
are highly expressed in the mammalian brain. STK24 kinase
activity increases during nerve regeneration and is required for
axon outgrowth [26]. In non-neuronal cells, STK24 and STK25
are activated/phosphorylated following oxidative stress promoting
apoptotic cell death [27,28]. It may be hypothesized that the
modulation of neurite outgrowth and oxidative stress resistance by
LRRK2 shown by others [3,4,21] is partly mediated by Ste20
kinases. LRRK2-mediated TAOK/MARKK phosphorylation
could be confirmed in an in-solution kinase assay using a kinase-
inactive TAOK/MARKK mutant. Thus, the present study may
provide the ‘missing link’ of a kinase signaling cascade
LRRK2RTAOK/MARKKRMARKRTau that may partially
explain enhanced Tau phosphorylation and axonal pathology in
brains from LRRK2 overexpressing mice and human PD patients
carrying a gain-of-function LRRK2(G2019S) mutation [4,7,9].
LRRK2 has been classified as receptor-interacting protein
kinase 7 (RIP7) according to sequence homology in the kinase
domain [19]. Our in vitro study indicates that LRRK2/RIP7 also
shares some functional features with other RIP kinases. Like RIP1-
4 [19], LRRK2 interacts with TNF receptor-associated factor 2
which may contribute to LRRK2 ubiquitination and proteasomal
degradation in cells. Similar to RIP3 [11], LRRK2 phosphorylates
other RIP kinase family members. Finally, we demonstrate that
LRRK2 interacts with PKC zeta both on protein arrays and in
mouse brain homogenates. While LRRK2 does not efficiently
phosphorylate PKC zeta in vitro, LRRK2 itself becomes phos-
phorylated by recombinant PKC zeta. Similar in vitro findings have
been reported when RIP4 and PKC beta/delta were tested [29].
Consistently, we identified several PKC consensus phosphoryla-
tion sites (K/RXXS*/T*) [30] within the LRRK2 protein by
sequence analysis. Finally, both PKC zeta (present study) and
LRRK2 [14] phosphorylate moesin on threonine-558 suggesting
that moesin may act as a common effector for regulation of neurite
elongation by brain-specific PKC/PKM zeta and LRRK2,
respectively [15,31].
In summary, our protein microarray analysis functionally links
PD-associated LRRK2 to Ste20 kinases and RIP kinases,
respectively, and identifies novel LRRK2 interactors/effectors
(e.g. STK24, STK25, TAOK/MARKK, PKC zeta) that may
contribute to its function in oxidative stress signaling and
structural/functional plasticity in neurons.
Supporting Information
Figure S1 Both LRRK2 and PKC zeta phosphorylate moesin in
vitro. (Upper panel) Autoradiogram showing phosphorylation of
GST-tagged moesin by co-incubation with: (lane 1 and 2)
recombinant PKC zeta and LRRK2(G2019S), (lane 3 and 4)
PKC zeta and kinase-dead LRRK2(D1994A), (lane 5 and 6) PKC
alone, and (lane 6 and 7) CDK5 as negative control. (Lower panel)
Coomassie Blue protein staining shows similar amounts of
recombinant GST-tagged moesin.
Found at: doi:10.1371/journal.pone.0013191.s001 (0.15 MB TIF)
Table S1 Genepix Pro and ProtoArray Prospector analysis of
protein arrays used for kinase substrate identification.
Found at: doi:10.1371/journal.pone.0013191.s002 (1.15 MB
XLS)
Table S2 Genepix Pro and ProtoArray Prospector analysis of
protein arrays used for protein-protein binding studies.
Found at: doi:10.1371/journal.pone.0013191.s003 (1.15 MB
XLS)
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